TENX Tenax Therapeutics, Inc.

0.75
-0.02  -1.73%
Previous Close 0.77
Open 0.77
Price To book 0.46
Market Cap 21.20M
Shares 28,119,000
Volume 526,826
Short Ratio 0.77
Av. Daily Volume 1,303,440

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b trial did not meet primary endpoint.
Levosimendan
Septic shock
Phase 3 top line data released January 31, 2017 - primary endpoints not met.
Levosimendan
Reduce the incidence of low cardiac output syndrome during cardiac surgery

Latest News

  1. TENX: Tenax Reports LEVO-CTS Topline Results
  2. Under Armour, Rite Aid Fall into Tuesday’s 52-Week Low Club
  3. Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery
  4. Biotech M&A Activity Expected to Rise in 2017: Latest Reports on Tenax Therapeutics and ZIOPHARM Oncology
  5. Tenax Therapeutics Inc (TENX) Might Be A Discount Opportunity Ahead Of January Release
  6. Tenax Therapeutics, Inc. Review of Clinical Trials and Financials
  7. Is KemPharm Inc (KMPH) A Good Stock To Buy?
  8. TENX: LEVO-CTS Enrolment Complete; Anticipate January Topline Readout
  9. Tenax Therapeutics Announces Completion of Enrollment for Phase 3 LEVO-CTS Trial in Cardiac Surgery
  10. Tenax Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update
  11. Tenax Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update
  12. Investor Calendar Invites You to the Tenax Therapeutics Third Quarter 2016 Business Review and Update on Thursday, November 10, 2016
  13. TENAX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  14. Tenax Therapeutics to Discuss Third Quarter 2016 Financial Results and Provide Business Update
  15. Tenax Therapeutics to Discuss Third Quarter 2016 Financial Results and Provide Business Update
  16. TENX: LeoPARDS Trial Fails Endpoints; Year End 2016 Readout for LEVO-CTS.
  17. Here’s What Happened With Alnylam Pharmaceuticals, Inc. (ALNY) and Tenax Therapeutics Inc (TENX)
  18. Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan
  19. Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan
  20. TENX: Higher Costs in FY:16; Dual Readouts in 4Q:16 Maintaining $10 Target